166 related articles for article (PubMed ID: 37750361)
1. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
Jin H; Kim MO; Scheffler A; Jiang F
Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
[TBL] [Abstract][Full Text] [Related]
2. Bayesian selective response-adaptive design using the historical control.
Kim MO; Harun N; Liu C; Khoury JC; Broderick JP
Stat Med; 2018 Nov; 37(26):3709-3722. PubMed ID: 29900577
[TBL] [Abstract][Full Text] [Related]
3. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
Harun N; Liu C; Kim MO
Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
[TBL] [Abstract][Full Text] [Related]
4. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
Sawamoto R; Oba K; Matsuyama Y
Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
[TBL] [Abstract][Full Text] [Related]
5. An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma.
Normington J; Zhu J; Mattiello F; Sarkar S; Carlin B
Contemp Clin Trials; 2020 Feb; 89():105890. PubMed ID: 31740427
[TBL] [Abstract][Full Text] [Related]
6. A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design.
Warren JL; Wang Q; Ciarleglio MM
Stat Med; 2024 Apr; 43(8):1615-1626. PubMed ID: 38345148
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
Zhang W; Pan Z; Yuan Y
J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
[TBL] [Abstract][Full Text] [Related]
8. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
9. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
10. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
11. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
12. Bayesian borrowing from historical control data in a vaccine efficacy trial.
Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
[TBL] [Abstract][Full Text] [Related]
13. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
Fu C; Pang H; Zhou S; Zhu J
Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
[TBL] [Abstract][Full Text] [Related]
15. A novel power prior approach for borrowing historical control data in clinical trials.
Shi Y; Li W; Liu GF
Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
Bennett M; White S; Best N; Mander A
Pharm Stat; 2021 May; 20(3):462-484. PubMed ID: 33474798
[TBL] [Abstract][Full Text] [Related]
18. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
19. Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.
Harun N; Gupta N; McCormack FX; Macaluso M
Clin Trials; 2023 Jun; 20(3):223-234. PubMed ID: 36927115
[TBL] [Abstract][Full Text] [Related]
20. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.
Hobbs BP; Carlin BP; Mandrekar SJ; Sargent DJ
Biometrics; 2011 Sep; 67(3):1047-56. PubMed ID: 21361892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
